Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Allergan
WARNING LETTER
•Allergan•August 31, 2011

Allergan – FDA Warning Letter, Aug 31, 2011

Record Details

The FDA issued a Warning Letter to Allergan for non-compliance with post-approval study (PAS) requirements for their NATRELLE Silicone-Filled Breast Implants (Round Responsive) and NATRELLE 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Style 410). These PASs were conditions of device approval under 21 C.F.R. § 814.82(a) to ensure continued safety and effectiveness.

For Round Responsive implants, Allergan failed to collect local complication and safety endpoint data during year 4 physician evaluations at a sufficient follow-up rate, which is critical for meeting the year 10 target. This deficiency, coupled with a decrease in participating IRB-approved sites, prevents adequate evaluation of the device's long-term safety and effectiveness.

For Style 410 implants, the firm failed to enroll the required 530 subjects in the redesigned study, having only enrolled (b)(4) subjects by August 2019, 30 months past the enrollment deadline, with enrollment subsequently halted due to a worldwide recall. This failure also impedes the adequate continuing evaluation of the device's safety and effectiveness.

Both failures violate 21 C.F.R. § 814.82(a)(2) and (9). The FDA warned that failure to promptly correct these issues could lead to the withdrawal of the Premarket Approval (PMA) under 21 C.F.R. § 814.82(c). Allergan is required to submit a corrective action plan or documentation of compliance within 15 working days, detailing steps taken, supporting evidence, and a timetable for ongoing corrections. The FDA also suggested considering alternative strategies to fulfill the PAS requirements.

Company
Allergan
Inspection date
August 31, 2011
Product type
Devices
Office
Center for Devices and Radiological Health
Person
  • Binita S. Ashar (Director)
View Company Profile

ID · 93523f05-273a-47d5-813b-b0492930a2b7

Violation Codes6
21 CFR 814.82(a)21 CFR 814.82(a)(2)21 CFR 814.82(a)(9)21 CFR 814.82(c)21 CFR 5621 CFR 50

Full citation text and observation details available on the Dashboard.

Other documents for Allergan
  • EIR - 2019-04-11April 11, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Allergan
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.